Saturday, May 3

Guwahati: A 17-year-old girl succumbed to suspected Guillain-Barré Syndrome (GBS) at a private hospital in Guwahati, marking the first reported fatality from the condition in Assam this season, as confirmed by medical professionals. However, the Assam State Health Department has not yet issued an official statement to confirm whether it is the first such fatality in the state.

The girl, who was admitted to Pratiksha Hospital on January 21, had a history of diarrhoea a week before her admission. She was diagnosed with GBS and had been on a ventilator for the past 11 days before passing away on January 31.

GBS is a rare neurological disorder where the body’s immune system attacks its nerves, causing weakness and numbness in limbs, face, and eyes. In severe cases, it can affect breathing, making it a potentially life-threatening condition.

A hospital spokesperson mentioned that the cause of GBS remains inconclusive in many cases, though it often follows viral or bacterial infections, including Campylobacter jejuni and Cytomegalovirus (CMV). Treatment typically includes IVIg injections or plasma exchange, a procedure similar to dialysis. While the girl’s family was planning to transfer her to Delhi for advanced treatment, her condition deteriorated before they could make the transfer, leading to her unfortunate passing.

The patient’s family had originally come from Bihar and had been residing in Assam for some time. The girl’s father is a Central Government employee.

Share.
Leave A Reply

Doctors Post is a news portal tailored to provide current news & updates on issues related exclusively to medical & healthcare professionals. The content of Doctor Post is judiciously authored by a dedicated team of legal experts, doctors and reporters.  The intent of the content is to expeditiously update doctor’s information & news necessary for the smooth functioning of their profession.

© 2024 Doctor Post. All Rights Reserved. Created and Maintained by Creative web Solution

Disclaimer: Use of the site is governed by our terms of use, privacy policy, and advertisement policy. For further details, please refer to our Disclaimer.

Exit mobile version